This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

Our Compounds

Our extensive oncology clinical trial programme has produced two approved drugs, as well as several other investigational compounds that are currently being investigated across a broad range of tumour types. Find out more below. 

Filter by:
Compound Target Focus area Development stage
  • Phase I
  • Phase II
  • Phase III
  • Approved

BI 754091 / BI 754111
NBE iv

  • PD-1/LAG3
  • Solid tumours
  1. 1
  2. 2
  3. 3
  4. A

BI 754091 / BI 891065
NCE po

  • PD-1/SMAC
  • Solid tumours
  1. 1
  2. 2
  3. 3
  4. A

Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information please click here. Nintedanib is not approved in other oncology indications.

Xentuzumab, BI 836858, BI 836880, BI 1361849, BI894999, BI 754091, BI 754111 and BI 891065 are investigational compounds and have not been approved. Their safety and efficacy have not been established.

 

Ang-2, angiopoietin-2; BET, bromodomain and extra terminal motif; CD, cluster of differentiation; EGFR, epidermal growth factor receptor; ErbB, epidermal growth factor receptor tyrosine kinase family receptor; FGFR, fibroblast growth factor receptor; HER2, human epidermal growth factor receptor 2; IGF, insulin-like growth factor; iv, intravenous; LAG3, lymphocyte activation gene 3 protein; MAGE, melanoma-associated antigen; mRNA-based ICV, messenger ribonucleic acid-based immunotherapeutic cancer vaccine; MUC1, mucin 1, cell surface associated; NBE, new biological entity; NCE, new chemical entity; NY-ESO-1, New York esophageal squamous cell carcinoma 1; PD-1, programmed cell death protein 1; po, orally; PDGFR, platelet-derived growth factor receptor; SMAC, second mitochondria-derived activator of caspase; TPBG, trophoblast glycoprotein; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial growth factor receptor.